Publications

Journal Articles

  1. & Semaglutide. Drugs of the Future
  2. & Cardiovascular events and all-cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes, Obesity and Metabolism
  3. & Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocrine Disorders 17(1)
  4. & Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology
  5. & Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology
  6. & Cardiovascular safety of liraglutide for the treatment of Type 2 diabetes. Expert Opinion on Drug Safety
  7. & Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology, 193229681773512
  8. & Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Primary Care Diabetes
  9. & Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial. Diabetes, Obesity and Metabolism 18(2), 196-199.
  10. & Omarigliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 17(14), 1947-1952.
  11. & Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine
  12. & Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Diabetes, Obesity and Metabolism
  13. & LEADER-4. Journal of Hypertension 34(6), 1140-1150.
  14. The Characteristics of Patients whose both Fasting and Postprandial Glucose were Controlled by Once Daily Basal Insulin Monotherapy. Journal of Diabetes & Metabolism 07(02)
  15. & LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovascular Diabetology 15(1)
  16. & Clinical use of the co-formulation of insulin degludec and insulin aspart. International Journal of Clinical Practice 70(8), 657-667.
  17. & Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, dc161525
  18. & Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, dc142883
  19. & Impact of single and multiple sets of resistance exercise in type 1 diabetes. Scandinavian Journal of Medicine & Science in Sports 25(1), e99-e109.
  20. & Similar risk of exercise-related hypoglycaemia for insulin degludec compared with insulin glargine in patients with type 1 diabetes: a randomised cross-over trial. Diabetes, Obesity and Metabolism, n/a-n/a.
  21. & Simulated games activity vs continuous running exercise: A novel comparison of the glycemic and metabolic responses in T1DM patients. Scandinavian Journal of Medicine & Science in Sports, n/a-n/a.
  22. & Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials. Diabetes Therapy 5(2), 435-446.
  23. & Reductions in resistance exercise-induced hyperglycaemic episodes are associated with circulating interleukin-6 in Type 1 diabetes. Diabetic Medicine 31(8), 1009-1013.
  24. & One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. Journal of Diabetes and its Complications 27(5), 492-500.
  25. & Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension. Journal of Clinical Endocrinology & Metabolism 98(3), 1154-1162.
  26. et. al. Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy. Diabetes 61(8), 2187-2194.
  27. & Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. Diabetes Care 35(7), 1446-1454.
  28. & Isomaltulose Improves Postexercise Glycemia by Reducing CHO Oxidation in T1DM. Medicine & Science in Sports & Exercise 43(2), 204
  29. & An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia 54(12), 3062-3070.
  30. & Association between the adiponectin promoter rs266729 gene variant and oxidative stress in patients with diabetes mellitus. European Heart Journal 30(10), 1263
  31. & Hypertriglyceridaemia is associated with an increased likelihood of albuminuria in extreme duration (> 50 years) Type 1 diabetes. Diabetic Medicine 25(10), 1234
  32. & Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy. Diabetologia 51(11), 1998-2002.
  33. & Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy. New England Journal of Medicine 351(19), 1952-1961.
  34. & The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. The Lancet 364(9446), 1699-1700.